OBJECTIVES: To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis. METHODS: Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen was identified through a combination of IPP and MALDI-TOF mass spectrometry, and confirmed using commercial antibodies and IPP-western blots. Additional samples from patients with DM (668), DM-overlap (80), PM-overlap (191), systemic sclerosis (150), systemic lupus erythematosus (200), Sjogren's syndrome (40), rheumatoid arthritis (50) and healthy controls (150) were serotyped by IPP as disease or healthy controls. RESULTS: IPP revealed a novel pattern in three PM patients (0.44%) that was not found in disease-specific or healthy control sera. Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern for all positive patients. Mass spectrometry analysis of the protein complex identified the target autoantigen as eIF3, a cytoplasmic complex with a role in the initiation of translation. Findings were confirmed by IPP-Western blotting. The three anti-eIF3-positive patients had no history of malignancy or interstitial lung disease, and had a favourable response to treatment. CONCLUSION: We report a novel autoantibody in 0.44% of PM patients directed against a cytoplasmic complex of proteins identified as eIF3. Although our findings need further confirmation, anti-eIF3 appears to correlate with a good prognosis and a favourable response to treatment.

Department of Musculoskeletal Biology 2 University of Liverpool Liverpool UK

Department of Rheumatology Leighton Hospital Crewe

Department of Rheumatology Manchester Royal Infirmary Manchester UK

Department of Rheumatology Salford Royal NHS Foundation Trust Manchester Academic Health Science Centre Salford UK

Division of Rheumatology Department of Medicine Karolinska Institutet Karolinska University Hospital Stockholm Sweden

Immunology Department of Internal Medicine University of Debrecen Debrecen Hungary

National Institute for Health Research Manchester University NHS Foundation Trust The University of Manchester Manchester

Pharmacy and Pharmacology University of Bath Bath

Rheumatology Charles University Prague Czech Republic

University Hospital Birmingham Queen Elizabeth Hospital Birmingham

See more in PubMed

Bohan A, Peter JB.. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7. PubMed

Bohan A, Peter JB.. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403–7. PubMed

McHugh NJ, Tansley SL.. Autoantibodies in myositis. Nat Rev Rheumatol 2018;14:290–302. PubMed

Betteridge Z, Tansley S, Shaddick G. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019;101:48. PubMed PMC

Pinal-Fernandez I, Mammen AL.. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol 2016;28:619–24. PubMed PMC

Hengstman GJ, ter Laak HJ, Vree Egberts WT. et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635–8. PubMed PMC

Mammen AL, Chung T, Christopher-Stine L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713–21. PubMed PMC

Lilleker JB, Vencovsky J, Wang G. et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018;77:30–9. PubMed PMC

LeRoy EC, Medsger TA Jr.. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6. PubMed

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. PubMed

Vitali C, Bombardieri S, Jonsson R. et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8. PubMed PMC

Arnett FC, Edworthy SM, Bloch DA. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24. PubMed

Lundberg IE, Tjärnlund A, Bottai M. et al. 2017 European League against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017;76:1955–64. PubMed PMC

Browning KS, Gallie DR, Hershey JW. et al. Unified nomenclature for the subunits of eukaryotic initiation factor 3. Trends Biochem Sci 2001;26:284. PubMed

Sha Z, Brill LM, Cabrera R. et al. The eIF3 interactome reveals the translasome, a supercomplex linking protein synthesis and degradation machineries. Mol Cell 2009;36:141–52. PubMed PMC

Lagirand-Cantaloube J, Offner N, Csibi A. et al. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 2008;27:1266–76. PubMed PMC

Csibi A, Tintignac LA, Leibovitch MP, Leibovitch SA.. eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy. Cell Cycle 2008;7:1698–701. PubMed

Docquier A, Pavlin L, Raibon A. et al. eIF3f depletion impedes mouse embryonic development, reduces adult skeletal muscle mass and amplifies muscle loss during disuse. J Physiol 2019;597:3107–31. PubMed